98-14497. Government-Owned Inventions; Availability for Licensing  

  • [Federal Register Volume 63, Number 105 (Tuesday, June 2, 1998)]
    [Notices]
    [Pages 30007-30008]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 98-14497]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    National Institutes of Health
    
    
    Government-Owned Inventions; Availability for Licensing
    
    AGENCY: National Institutes of Health, Pubic Health Service, DHHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The inventions listed below are owned by agencies of the U.S. 
    Government and are available for licensing in the U.S. in accordance 
    with 35 U.S.C. 207 to achieve expeditious commercialization of results 
    of federally-funded research and development. Foreign patent 
    applications are filed on selected inventions to extend market coverage 
    for companies and may also be available for licensing.
    
    ADDRESSES: Licensing information and copies of the U.S. patent 
    applications listed below may be obtained by writing to the indicated 
    licensing contact at the Office of Technology Transfer, National 
    Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
    Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
    signed Confidential Disclosure Agreement will be required to receive 
    copies of the patent applications.
    
    Applicator System And Method Of Use
    
    MJ Lenardo, G Fisher (NIAID)
    
    Serial No. 09/005,475 Filed 12 Jan 98
        Licensing Contact: John Fahner-Vihtelic, 301/496-7735 ext. 270.
        The present application describes a novel microcentrifuge tube and 
    tube cap and research method, which allows for dispensing the contents 
    of a microcentrifuge tube without pipetting. The design eliminates 
    pipetting volume error and prevents the cross-contamination which can 
    be experienced in conventional pipetting. This invention is 
    particularly useful for such applications as loading tube contents into 
    an electrophoresis gel after a reaction such as PCR. Using the 
    disclosed apparatus and methods increases the speed of a variety of 
    routine procedures and prevents contamination of samples due to soiled 
    lab apparatus.
    
    Linking Compounds Useful For Coupling Carbohydrates To Amine-
    Containing Carriers
    
    P Kova, J Zhang (NIDDK)
    
    Serial No. 60/069,686 Field 12 Dec 97
        Licensing Contact: Robert Benson, 301/496-7056 ext. 267.
        This invention describes an inexpensive and easy method of linking 
    carbohydrates and carriers containing an amino group to form 
    neoglycoconjugates. The resulting neoglycoconjugates are useful as 
    vaccines (i.e., bacterial LPS or LOS-carrier protein conjugate 
    vaccines) or as biologically active chromatographic substrates (i.e., 
    carbohydrates bound to aminopropyl glass). The method involves specific 
    linkers that are easily made from inexpensive commercially available 
    starting materials. The carbohydrates to be used in the method are 
    limited only by the ability to convert such carbohydrates into glycosyl 
    donors. Claimed are the linkers, conjugates made with the linkers and 
    intermediates, and methods of synthesizing the linkers and conjugates. 
    The invention is described in Tetrahedron letters 39, 1091-1094, 1998.
    
    System And Method For Intelligent Quality Control Of A Process
    
    JM DeLeo (CIT), AT Remaley (CC)
    
    Serial No. 60/066,624 Filed 26 Nov 97
        Licensing Contact: John Fahner-Vihtelic, 301/496-7735 ext. 270.
        The present application is a methodology for monitoring the quality 
    control of a process on-line for the purpose of predicting and 
    preventing unusual/untoward events or failures in that process. Such 
    processes include (but are not limited to) acquisition of medical data 
    from laboratory instruments, assembly line manufacturing, and general 
    plant or factory operations. The methodology is based on a two-tiered 
    automated intelligent agent architecture. Intelligent agents in the 
    first tier are neural networks trained to detect specific errors for 
    specific process environment parameters. The single-agent second tier 
    is an expert system that integrates inputs from first tier agents to 
    derive corrective action decisions that are manually or automatically 
    executed in the process environment. Error prevalence and wrong-
    decision cost information are factored into the action decision-making 
    process. For clinical laboratory instruments, the method monitors 
    patient laboratory data and provides significant improvement in quality 
    control at reduced cost compared to existing methods.
    
    Identification Of The Human Pendred Syndrome Gene
    
    E Green, et al. (NHGRI)
    
    DHHS Reference No. E-004-98/0 Filed 28 Oct 97
        Licensing Contact: Dennis Penn, 301/496-7065, ext. 211.
        Pendred syndrome is a recessively inherited disorder which was 
    poorly understood until the discovery of the Pendred syndrome gene. 
    This syndrome, which is associated with congenital deafness and thyroid 
    goiter, may account for upwards of 10% of hereditary deafness. The gene 
    encodes for the protein pendrin which transports sulfate across cell 
    membranes. However, the gene, when mutated, is responsible for 
    producing defective pendrin and causing Pendred syndrome. Pendrin 
    therefore plays a key role in thyroid function and the development and 
    functioning of the auditory system. Learning how pendrin functions 
    could lead to a better understanding of thyroid function and the 
    development of the auditory system. Finally, the resulting knowledge 
    into the genetic basis of Pendred syndrome will allow for improved 
    diagnosis of syndrome-specific mutations in at-risk individuals. This 
    research has been published in Nature Genetics 1997 December; 
    17(4):411-22.
    
    Local Magnetization Spoiling Using A Gradient Insert For Reducing 
    The Field Of View In Magnetic Resonance Imaging
    
    DG Wiesler, H Wen, RS Balaban, SD Wolff (NHLBI)
    
    Serial No. 60/043,292 Filed 11 Apr 97
        Licensing Contact: John Fahner-Vihtelic, 301/496-7735, ext. 270.
        The present invention provides a method and device for eliminating 
    alias artifacts encountered in MRI when the field of view is made 
    smaller than the subject being imaged. Significant
    
    [[Page 30008]]
    
    advantages accrue from reducing the field of view to a smaller region 
    of interest. These include reduced imaging time, increased spatial and 
    temporal resolution, and less susceptibility to motion artifacts. The 
    device operates by dephasing the magnetic resonance signal in regions 
    away from the region of interest by means of a gradient insert.
    
    Nitrogen-Containing Cylohetero Cycloalkyl-Aminoaryl Derivatives For 
    CNS Disorders
    
    BR DeCosta, et al. (NIDDK)
    
    Serial No. 07/473,008 Filed 31 Jan 90 (U.S. Patent 5,130,330 Issued on 
    14 Jul 92); Serial No. 07/877,190 Filed 01 Jul 92 (U.S. Patent 
    5,739,158 Issued on 14 Apr 98); Serial No. 08/335,532 Filed 07 Nov 94
        Licensing Contact: Charles Maynard, 301/496-7735, ext. 243.
        This technology includes compositions for a novel family of 
    nitrogen containing cyclohetero cycloalkyl-aminoaryl compounds for use 
    in the field of clinical neurology. The intellectual property relates 
    specifically to a class of therapeutically useful compounds for the 
    treatment of central nervous system (CNS) disorders such as cerebral 
    ischemia, psychotic disorders and convulsions. These compounds are 
    particularly useful for treating neurotoxic injury which follow periods 
    of hypoxia, anoxia or ischemia associated with stroke, cardiac arrest 
    or perinatal asphyxia.
        The novel semirigid derivatives (+)-cis-1-[2-phenyl-2-
    bicyclo[3,1,0]hexyl]piperidine [(+)-8], its enantiomer (-)-8, and (+-)-
    trans-1-[2-phenyl-2-bicylo [3,1,0]piperidine [(+/-)-9] are illustrative 
    examples of this family of compounds which may be used to treat CNS 
    disorders and diseases such as cerebral ischemia, psychotic disorders 
    and convulsions, as well as prevention of neurotoxic damage and 
    neurodegenerative disease via a unique receptor mechanism. This class 
    of compounds produce neuroprotective effects by a different mechanism 
    to phencyclidine and metaphit a non-competitive N-methyl-D-aspartic 
    acid antagonis.
    
        Dated: May 21, 1998.
    Jack Spiegel,
    Director, Division of Technology, Development, and Transfer, Office of 
    Technology Transfer.
    [FR Doc. 98-14497 Filed 6-1-98; 8:45 am]
    BILLING CODE 4140-01-M
    
    
    

Document Information

Published:
06/02/1998
Department:
National Institutes of Health
Entry Type:
Notice
Action:
Notice.
Document Number:
98-14497
Pages:
30007-30008 (2 pages)
PDF File:
98-14497.pdf